Fexapotide TFA
Fexapotide (NX-1207) TFA induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research.
For research use only. We do not sell to patients.
- Formula: C90H163N27O25S.xC2HF3O2
- Molecular Weight:2055.49 (free base)
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Chemical Information
-
Molecular Weight 2055.49 (free base)
-
Formula C90H163N27O25S.xC2HF3O2
-
Synonyms
NX-1207 TFA
-
Sequence
Ile-Asp-Gln-Gln-Val-Leu-Ser-Arg-Ile-Lys-Leu-Glu-Ile-Lys-Arg-Cys-Leu
-
Sequence Shortening
IDQQVLSRIKLEIKRCL
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Shore N, et al. Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia. Ther Adv Urol. 2019 Jan 14;11:1756287218820807. [Content Brief]
[2]. Shore N, et al. Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement. World J Urol. 2018 May;36(5):801-809. [Content Brief]
[3]. Shore N, et al. The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians. Ther Adv Chronic Dis. 2011 Nov;2(6):377-83. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Fexapotide TFA Related Classifications
HY-P3501A Related Classifications
Powered by Bioz